These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 24378839)
1. Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests. Valgimigli M J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S8-S15. PubMed ID: 24378839 [TBL] [Abstract][Full Text] [Related]
2. Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel. Cattaneo M J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S16-21. PubMed ID: 24378837 [TBL] [Abstract][Full Text] [Related]
3. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Bernlochner I; Byrne RA; Kastrati A; Sibbing D Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045 [TBL] [Abstract][Full Text] [Related]
4. New antiplatelet agents and the role of platelet function testing in acute coronary syndromes. Sinhal AR; Aylward PE Clin Ther; 2013 Aug; 35(8):1064-8. PubMed ID: 23973039 [TBL] [Abstract][Full Text] [Related]
5. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice. Golino P J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838 [TBL] [Abstract][Full Text] [Related]
6. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525 [TBL] [Abstract][Full Text] [Related]
7. Prognostic role of platelet reactivity in patients with acute coronary syndromes. Cavallari I; Nusca A; Ricottini E; Di Sciascio G Cardiol Rev; 2014; 22(6):313-8. PubMed ID: 25050977 [TBL] [Abstract][Full Text] [Related]
9. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy. Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395 [TBL] [Abstract][Full Text] [Related]
10. Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS? Aradi D; Komócsi A Platelets; 2012; 23(3):167-76. PubMed ID: 21958190 [TBL] [Abstract][Full Text] [Related]
13. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816 [TBL] [Abstract][Full Text] [Related]
14. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial. Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268 [TBL] [Abstract][Full Text] [Related]
16. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. Tantry US; Bonello L; Aradi D; Price MJ; Jeong YH; Angiolillo DJ; Stone GW; Curzen N; Geisler T; Ten Berg J; Kirtane A; Siller-Matula J; Mahla E; Becker RC; Bhatt DL; Waksman R; Rao SV; Alexopoulos D; Marcucci R; Reny JL; Trenk D; Sibbing D; Gurbel PA; J Am Coll Cardiol; 2013 Dec; 62(24):2261-73. PubMed ID: 24076493 [TBL] [Abstract][Full Text] [Related]
17. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250 [TBL] [Abstract][Full Text] [Related]
18. Latest clinical data on testing for high on-treatment platelet reactivity. Fileti L; Campo G; Valgimigli M Rev Cardiovasc Med; 2011; 12 Suppl 1():S14-22. PubMed ID: 22080983 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. Morel O; El Ghannudi S; Jesel L; Radulescu B; Meyer N; Wiesel ML; Caillard S; Campia U; Moulin B; Gachet C; Ohlmann P J Am Coll Cardiol; 2011 Jan; 57(4):399-408. PubMed ID: 21251579 [TBL] [Abstract][Full Text] [Related]
20. Evolving role of platelet function testing in coronary artery interventions. Sharma RK; Voelker DJ; Sharma R; Reddy HK; Dod H; Marsh JD Vasc Health Risk Manag; 2012; 8():65-75. PubMed ID: 22371653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]